Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H1 2016

  • ID: 3753875
  • Drug Pipelines
  • 53 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Actelion Ltd
  • Eisai Co., Ltd.
  • Evotec AG
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • MORE
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H1 2016

Summary

‘Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H1 2016’, provides in depth analysis on Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2)
- The report reviews Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Actelion Ltd
  • Eisai Co., Ltd.
  • Evotec AG
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) Overview

Therapeutics Development

Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Stage of Development

Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Therapy Area

Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Indication

Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Companies

Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development

Actelion Ltd

Eisai Co., Ltd.

Evotec AG

Heptares Therapeutics Limited

Johnson & Johnson

Merck & Co., Inc.

Novartis AG

Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles

DORA-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-6641 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-42847922 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lemborexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8133 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit OX2R for Insomnia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Dormant Projects

Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products

Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Featured News & Press Releases

Mar 11, 2016: Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202

Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients

Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder

Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous System Product Candidate MIN-202

Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist

Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist

Feb 03, 2015: Merck’s Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States

Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia

Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance

Nov 26, 2014: Merck announces launch of Berusomura tablets15mg/20mg in Japan

Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial

Aug 13, 2014: FDA Approves BELSOMRA for the Treatment of Insomnia

Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck’s Investigational Medicine for Insomnia

May 22, 2013: Merck Wins FDA Panel Recommendation For Insomnia Drug Suvorexant At Lower Dose

May 20, 2013: Merck's Experimental Insomnia Drug Safe But May Carry Troublesome Side Effects, FDA Staff Says

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Actelion Ltd, H1 2016

Pipeline by Eisai Co., Ltd., H1 2016

Pipeline by Evotec AG, H1 2016

Pipeline by Heptares Therapeutics Limited, H1 2016

Pipeline by Johnson & Johnson, H1 2016

Pipeline by Merck & Co., Inc., H1 2016

Pipeline by Novartis AG, H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Actelion Ltd
Eisai Co., Ltd.
Evotec AG
Heptares Therapeutics Limited
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll